Browsing: Alzheimers

An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers reported Tuesday

For most of the past few decades, scientists chasing treatments for Alzheimer’s disease have focused on attacking the buildup of one protein in the brain that contributes to the disease: amyloid. They’ve had some success; there are currently two anti-amyloid treatments approved

The University of Cincinnati and UC Health have launched the Center for Alzheimer’s and Neurodegenerative Diseases Research (CANDR), a multidisciplinary initiative that integrates research with clinical and educational expertise to improve dementia prevention and treatment outcomes throughout the Greater Cincinnati community and beyond

NEW YORK (WABC) –Capt. Chesley “Sully” Sullenberger, who famously landed a plane on the Hudson River in New York City in 2009, has revealed he was diagnosed with Alzheimer’s disease

An experimental drug might help slow early Alzheimer’s disease in a markedly different way than current treatments — by lowering the brain’s production of a protein called tau

NEW YORK –Capt. Chesley “Sully” Sullenberger, who famously landed a plane on the Hudson River in New York City in 2009, has revealed he was diagnosed with Alzheimer’s disease

The U.S. Pointer Study, a two-year landmark clinical trial, enrolled more than 2,000 people at risk for Alzheimer’s disease, looking at lifestyle changes and its affect on brain health

The Alzheimer’s Association has launched a new global clinical trial investigating whether combining a proven multidomain lifestyle intervention with a GLP-1 agonist can further reduce the risk of cognitive decline, mild cognitive impairment (MCI) and dementia in at-risk older adults.

– LatAm-FINGERS Study Findings Confirm and Expand U.S. POINTER Trial Results — Show Structured Dementia Risk Reduction Strategies Adaptable Across Cultures –

July 13, 2026 /PRNewswire/ — The Alzheimer’s Association today announced the launch of the PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy), a first-of-its-kind global clinical trial designed to evaluate whether combining a proven multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk of cognitive…